Last reviewed · How we verify
NCT03049956
OVEMP in Myasthenia
NA trial testing Ocular vestibular evoced myogenic potentials in Myasthenia Gravis, Ocular in 96 participants. Completed.
31 December 2020
Quick facts
| Lead sponsor | University of Zurich |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Primary purpose | diagnostic |
| Enrollment | 96 |
| Start date | 1 November 2016 |
| Primary completion | 31 December 2020 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Ocular vestibular evoced myogenic potentials
Conditions studied
- Myasthenia Gravis, Ocular — all drugs for Myasthenia Gravis, Ocular →
Sponsor
University of Zurich
Who can join
18 and older, any sex, with Myasthenia Gravis, Ocular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Myasthenia gravis is an autoimmune disorder of neuromuscular transmission, characterized by fluctuating muscle weakness and fatigability. In isolated ocular myasthenia, when only the extraocular muscles are involved, most common ancillary tests, such as acetylcholine receptor autoantibodies and repetitive nerve stimulation, are often negative. A simple, quick and non-invasive test for ocular myasthenia based on ocular vestibular evoked myogenic potentials (oVEMP) was recently developed. The main goal of the study is to validate repetitive oVEMP stimulation in a blinded diagnostic accuracy study in order to facilitate early and accurate diagnosis of ocular myasthenia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
Valko Y, Wirth MA, Fierz FC, Schesny MK, et al · · 2024 · cited 2× · PMID 38669629 · DOI 10.1212/wnl.0000000000209395
Verify or expand the search:
- PubMed search for NCT03049956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myasthenia Gravis, Ocular
Currently open trials in the same condition.
- NCT07249632 — A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) · Phase 3 · recruiting
- NCT05214612 — Predictors and Prognostic Factors of Myasthenia Gravis Outcome · recruiting
- NCT06617741 — Myasthenia Gravis Foundation of America Global MG Patient Registry · recruiting
Other University of Zurich trials
Trials by the same sponsor.
- NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
- NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
- NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03049956 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Zurich
- Last refreshed: 11 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03049956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing